Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

Theratope® Study Group; David Miles; Henri Roché; Miguel Martin; Timothy J Perren; David A Cameron; John Glaspy; David Dodwell; Joanne Parker; José Mayordomo; Alejandro Tres; James Lee Murray; Nuhad K Ibrahim

doi:10.1634/theoncologist.2010-0307

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

Theratope® Study Group, David Miles, Henri Roché, Miguel Martin, Timothy J Perren, David A Cameron, John Glaspy, David Dodwell, Joanne Parker, José Mayordomo, Alejandro Tres, James Lee Murray, Nuhad K Ibrahim

Research output: Contribution to journal › Article › peer-review

Abstract

This double-blind, randomized, phase III clinical trial evaluated time to progression (TTP) and overall survival in women with metastatic breast cancer (MBC) who received sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine. Secondary endpoints included vaccine safety and immune response.

Original language	English
Pages (from-to)	1092-100
Number of pages	9
Journal	The Oncologist
Volume	16
Issue number	8
DOIs	https://doi.org/10.1634/theoncologist.2010-0307
Publication status	Published - 2011

Access to Document

10.1634/theoncologist.2010-0307

Phase III multicenter clinical trial of the sialyl-TN
The Oncologist 2011. Europepmc open access option
Final published version, 1.51 MB

http://theoncologist.alphamedpress.org/content/16/8/1092

Cite this

Theratope® Study Group, Miles, D., Roché, H., Martin, M., Perren, T. J., Cameron, D. A., Glaspy, J., Dodwell, D., Parker, J., Mayordomo, J., Tres, A., Murray, J. L., & Ibrahim, N. K. (2011). Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. The Oncologist, 16(8), 1092-100. https://doi.org/10.1634/theoncologist.2010-0307

@article{38e62cc29f414e96ab0d4a1d767abc34,

title = "Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer",

abstract = "This double-blind, randomized, phase III clinical trial evaluated time to progression (TTP) and overall survival in women with metastatic breast cancer (MBC) who received sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine. Secondary endpoints included vaccine safety and immune response.",

author = "{Theratope{\textregistered} Study Group} and David Miles and Henri Roch{\'e} and Miguel Martin and Perren, {Timothy J} and Cameron, {David A} and John Glaspy and David Dodwell and Joanne Parker and Jos{\'e} Mayordomo and Alejandro Tres and Murray, {James Lee} and Ibrahim, {Nuhad K}",

year = "2011",

doi = "10.1634/theoncologist.2010-0307",

language = "English",

volume = "16",

pages = "1092--100",

journal = "The Oncologist",

issn = "1083-7159",

publisher = "Oxford University Press",

number = "8",

}

Theratope® Study Group, Miles, D, Roché, H, Martin, M, Perren, TJ, Cameron, DA, Glaspy, J, Dodwell, D, Parker, J, Mayordomo, J, Tres, A, Murray, JL & Ibrahim, NK 2011, 'Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer', The Oncologist, vol. 16, no. 8, pp. 1092-100. https://doi.org/10.1634/theoncologist.2010-0307

TY - JOUR

T1 - Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

AU - Theratope® Study Group

AU - Miles, David

AU - Roché, Henri

AU - Martin, Miguel

AU - Perren, Timothy J

AU - Cameron, David A

AU - Glaspy, John

AU - Dodwell, David

AU - Parker, Joanne

AU - Mayordomo, José

AU - Tres, Alejandro

AU - Murray, James Lee

AU - Ibrahim, Nuhad K

PY - 2011

Y1 - 2011

N2 - This double-blind, randomized, phase III clinical trial evaluated time to progression (TTP) and overall survival in women with metastatic breast cancer (MBC) who received sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine. Secondary endpoints included vaccine safety and immune response.

AB - This double-blind, randomized, phase III clinical trial evaluated time to progression (TTP) and overall survival in women with metastatic breast cancer (MBC) who received sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine. Secondary endpoints included vaccine safety and immune response.

UR - http://www.scopus.com/inward/record.url?scp=80052206741&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2010-0307

DO - 10.1634/theoncologist.2010-0307

M3 - Article

C2 - 21572124

VL - 16

SP - 1092

EP - 1100

JO - The Oncologist

JF - The Oncologist

SN - 1083-7159

IS - 8

ER -

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this